Shanghai Sharks clinched the 2025-2026 CBA championship, but foreign centre Whiteside faces a two-year ban after testing positive for prohibited substances during the May 6 home game against Shandong Hi-Speed Kirin. The title remains, yet the roster depth takes a hit.
What happened?
China Anti-Doping Agency (Chinada) announced on Friday that Whiteside’s urine sample contained oxandrolone metabolites (class S1 anabolic agents) and clomifene (class S4 hormone and metabolic modulator). He waived his right to a B‑sample test. The violation occurred in the sixth game of the first‑round playoff series, which Shanghai won 112‑98.
Why does it matter for Shanghai Sharks?
At 37, Whiteside spent a decade in the NBA before joining Shanghai in 2024, becoming a key paint presence. During the playoffs he averaged 15.2 points, 9.8 rebounds, and 2.3 blocks and stayed efficient in the semi‑finals against Beijing Ducks. The ban sidelines him for the finals and the entire 2026‑2027 season, forcing the club to re‑tool its interior game and rely more on domestic big men.
What comes next?
While Whiteside is suspended, Shanghai Sharks retain their 2025‑2026 championship. The Chinese Basketball Association has confirmed no team‑level sanctions will be applied. Head coach Wang Han said the squad will lean on Wang Zhelin and younger front‑court players, experimenting with more pick‑and‑roll and transition offense in the upcoming preseason. Fans and analysts will watch closely to see if the Sharks can stay competitive without their veteran foreign centre.